Catalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for ALLO-329 [CD19/CD70 Dual CAR] in Autoimmune disease. The expected timing is based on the latest available company guidance and may change.
05/13/26:- RESOLUTION treated nine patients. Early activity seen, with next update expected Q4 2026. 08/12/26:- RESOLUTION enrollment continued briskly. Clinical and translational data will be updated in Q4 2026.
Verification
Confirm timing and program details against the company announcement or filing.